INCB099280 for Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called INCB099280 to see if it is safe and effective for patients with certain types of solid tumors. Researchers want to understand how the drug behaves in the body and its early effects on cancer.
Do I need to stop my current medications to join the trial?
The trial requires a 28-day period without taking systemic antibiotics before starting the study drug. Probiotics are not allowed during the study and screening. For other medications, the protocol does not specify, so it's best to discuss with the trial team.
Research Team
Incyte Medical Monitor
Principal Investigator
Incyte Corporation
Eligibility Criteria
This trial is for adults with advanced solid tumors who have tried all other treatments without success or can't tolerate them. They should be relatively healthy otherwise, able to perform daily activities with ease (ECOG score of 0-1), and not planning to conceive. People with heart issues, untreated brain metastases, active infections, or recent use of certain drugs can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive INCB099280 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- INCB099280
Find a Clinic Near You
Who Is Running the Clinical Trial?
Incyte Corporation
Lead Sponsor
Steven Stein
Incyte Corporation
Chief Medical Officer since 2015
MD from University of Witwatersrand
Hervé Hoppenot
Incyte Corporation
Chief Executive Officer since 2014
MBA from ESSEC Business School